Skip to main content
Premium Trial:

Request an Annual Quote

Agendia, Imegen Ink Distribution Deal for Breast Cancer Tests in Spain, Portugal

NEW YORK (GenomeWeb) – Agendia said today that it has signed an agreement with Valencia, Spain-based Imegen for the exclusive distribution of Agendia's MammaPrint and BluePrint breast cancer genomic tests in Spain and Portugal.

MammaPrint measures the expression of 70 genes and classifies patients as either high risk or low risk of recurrence over a 10-year period. BluePrint is an 80-gene assay that classifies patients as having either basal, luminal, or HER2 subtypes of breast cancer to further guide treatments.

Both tests are based on microarray technology. Agendia also separately markets the MammaPrint and BluePrint Breast Cancer Recurrence and Molecular Subtyping Kits using next-generation RNA sequencing technology.

"We are very pleased to have Imegen as a partner in the distribution of MammaPrint and BluePrint because of their knowledge in the area of oncological genomics and experience in the Spanish market," Agendia CEO Mark Straley said in a statement. "Together, we will bring our testing expertise to the nearly 25,000 women annually diagnosed with breast cancer on the Iberian Peninsula."

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.